4.4 Article

Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma

期刊

HEMATOLOGICAL ONCOLOGY
卷 40, 期 5, 页码 885-893

出版社

WILEY
DOI: 10.1002/hon.3073

关键词

DLBCL; MYD88 mutations; next generation sequencing; non-L265P

向作者/读者索取更多资源

MYD88 mutation has a significant impact on the prognosis of DLBCL patients. Compared with L265P mutation, non-L265P mutations occur less frequently in DLBCL of the central nervous system and breast tissue and have a lower coexistence rate with PIM1 mutation. Patients with DLBCL with MYD88 non-L265P mutation have a statistically better progression-free survival.
Diffuse large B-cell lymphoma (DLBCL) is a group of heterogeneous tumors with different molecular traits and clinical features. MYD88 is an oncogene that activates the nuclear factor kappa B pathway in DLBCL. MYD88 L265P mutation frequently occurs in DLBCL with poor prognosis, while the clinical significance of non-L265P mutations needs to be clarified. Next-generation sequencing was performed on a cohort of 356 patients with DLBCL to investigate the impact of MYD88 mutation. Ten MYD88 mutated variants were detected in 32% (114/356) of the cases. V217F, S219C, S222R, M232T, S243N, and T294P were identified as pathogenic variants. MYD88 non-L265P mutations occurred less than L265P mutation in DLBCL of the central nervous system and breast tissue. The coexistence of MYD88 non-L265P mutations with PIM1 mutation was also less than that of L265P mutation. The progression-free survival in patients with DLBCL with MYD88 non-L265P mutation was statistically better than in patients with MYD88 L265P mutation. The interpretation of variants of MYD88 mutation offers a precise guide for the management of DLBCL.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据